SCHEMBL15467712

SCHEMBL15467712

NC1(c2ccc(C(F)(F)F)cc2)CCOc2cccnc21

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.35
MAOA P21397 2/20 0.34
MAOB P27338 2/20 0.34
KDM1A O60341 1/20 0.34
SLC6A3 Q01959 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRL1 P41146 1/20 0.34
TRPV1 Q8NER1 2/20 0.34
P2RX7 Q99572 4/20 0.33
AKT1 P31749 1/20 0.33
AKT2 P31751 1/20 0.33
KIF11 P52732 1/20 0.32
EPHX2 P34913 2/20 0.32
APP P05067 1/20 0.32
BACE1 P56817 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15467859 1.00 TRPM8 (0.35) TRPM8MAOAMAOBKDM1ASLC6A3
Hydrochloric Acid SCHEMBL16413828 0.99 TRPM8 (0.35) TRPM8MAOAMAOBKDM1ASLC6A3
Hydrochloric Acid SCHEMBL15567769 0.99 TRPM8 (0.35) TRPM8MAOAMAOBKDM1ASLC6A3
SCHEMBL16421213 0.84 TRPM8 (0.49) TRPM8SLC6A3BACE1
SCHEMBL15467910 0.84 TRPM8 (0.49) TRPM8SLC6A3BACE1
SCHEMBL15469377 0.84 AKT1 (0.33) TRPM8AKT1AKT2
SCHEMBL15469390 0.84 AKT1 (0.33) TRPM8AKT1AKT2
SCHEMBL16418760 0.83 TRPM8 (0.35) TRPM8AKT1AKT2
Hydrochloric Acid SCHEMBL15567851 0.83 TRPM8 (0.49) TRPM8SLC6A3BACE1
SCHEMBL15467719 0.83 PDE2A (0.38) TRPM8KDM1AAKT1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885MAOA 601/4885MAOB 1631/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885MAOA 601/4885MAOB 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.